Highlights

  • Emyria shares rose 2.5% to AUD 0.041 during the morning session on 28 May 2026.
  • The gain followed a TGA update relating to psychedelic-assisted psychotherapy workforce recommendations.
  • The revised framework broadens the range of clinicians eligible within the therapy “dyad”.
  • Emyria expects the changes to support recruitment and improve clinic utilisation across its Empax network.
  • Benefits are anticipated to begin taking effect in H2 CY2026 following final endorsement and implementation.
  • The company has already commenced workforce planning ahead of the proposed changes.

Emyria Limited (ASX:EMD) shares moved 2.5% higher to AUD 0.041 during the morning session on 28 May 2026 after the company welcomed a Therapeutic Goods Administration (TGA) update relating to psychedelic-assisted psychotherapy (PAT) under the Authorised Prescriber (AP) scheme.

The market reaction followed an announcement that the regulator had updated recommendations surrounding the clinician requirements for psychedelic-assisted psychotherapy treatment delivery. Emyria believes the revised framework could broaden recruitment opportunities across its national Empax clinic network and improve operational flexibility over time.

The latest development is considered favourable for the company because it may reduce reliance on a narrower pool of clinicians while potentially supporting patient access and clinic scalability across Australia.

Emyria is an ASX-listed healthcare company focused on developing and delivering mental health and neurological treatments through a combination of clinical services, data collection and treatment development programs. The company operates through its Empax clinics and broader healthcare platform while also advancing psychedelic-assisted therapies and other emerging mental health treatment approaches.

TGA Revises Psychedelic Therapy Workforce Recommendations

Under the updated recommendations announced by the TGA, the range of clinicians eligible to participate within the psychedelic-assisted psychotherapy “dyad” has been expanded.

Previously, the treatment framework required either a clinical psychologist or medical practitioner to be present during dosing sessions. The revised recommendations now allow a broader group of trained professionals registered with certain national boards to participate within the therapy model.

According to the update, eligible disciplines can now include psychology professionals with clinical endorsement, medically registered practitioners, nursing and midwifery professionals with mental health experience, and occupational therapists where their scope of practice includes psychedelic-assisted psychotherapy.

The TGA also indicated that Authorised Prescribers may exercise professional discretion regarding additional therapy team members. These may include psychotherapists, counsellors, social workers, and Aboriginal and Torres Strait Islander health workers.

Emyria stated that it welcomed the inclusion of Aboriginal and Torres Strait Islander health workers as part of the broader recommendations, noting that the change may help support culturally appropriate care pathways across Australia.

Potential Recruitment Benefits for Empax Network

A major focus of the company’s announcement was the expected operational impact on its Empax clinic network.

Emyria currently maintains an Australia-wide clinician network of more than 100 professionals linked to Empax clinics. The company believes the revised recommendations could improve recruitment flexibility across multiple jurisdictions and support clinic utilisation levels.

According to Emyria, the broader workforce eligibility profile may help reduce reliance on clinical psychologists while enabling more adaptable therapy team structures.

Management also expects the revised framework to support workforce Diversification and improve access to treatment Options for patients across the company’s national footprint.

The company noted that revised therapist eligibility may accelerate recruitment processes by expanding the available pool of appropriately qualified professionals capable of participating in psychedelic-assisted psychotherapy delivery.

This may become increasingly relevant as interest in alternative mental health treatment pathways continues to evolve within Australia’s regulated healthcare environment.

Implementation Expected in H2 CY2026

While the recommendations have been announced, Emyria indicated that final approval and endorsement processes are still required before the changes formally take effect.

The company expects implementation benefits to begin materialising during the second half of calendar year 2026.

Emyria stated that it has previously navigated similar regulatory approval processes and will now be required to update existing care models before submitting them for ethics committee review and final TGA endorsement.

The company also confirmed that workforce planning activities have already commenced in preparation for the anticipated regulatory changes.

Management suggested that early preparation may position the Business to respond more efficiently once the updated framework becomes operational.

Regulatory Engagement Viewed Positively

Emyria characterised the TGA announcement as a pragmatic regulatory adjustment informed by growing clinical experience and real-world evidence relating to psychedelic-assisted psychotherapy.

The company indicated that it sees the regulator as increasingly engaged with evolving treatment frameworks and operational realities within the sector.

Executive Chair Greg Hutchinson said the updated recommendations could directly support therapist recruitment efforts while helping diversify Emyria’s workforce and improve patient access across the Empax network.

He also suggested that further refinements to the framework may emerge over time as clinical evidence and operational experience continue to develop.

The company’s comments indicate that management views the latest changes not only as an operational opportunity, but also as a broader signal of continued regulatory engagement with emerging mental health therapies in Australia.

Empax Network and Mental Health Focus

Emyria’s Empax clinics form part of the company’s broader mental health treatment strategy.

The business focuses on patients who may not have achieved sufficient outcomes through conventional treatment pathways, while also evaluating emerging therapies including psychedelic-assisted treatment approaches for conditions such as post-traumatic stress disorder and treatment-resistant depression.

In addition to direct healthcare services, Emyria also operates a Real-World Data platform designed to support therapy evaluation and future Drug Development initiatives.

The company’s broader pipeline includes psychedelic-assisted therapies and other treatment programs targeting mental health and select neurological conditions.

Management believes its integrated operating model — combining healthcare delivery, data collection and treatment development — provides a framework for evaluating emerging therapies while maintaining direct patient engagement.

Growing Industry Attention on Psychedelic-Assisted Therapies

Australia remains one of the more closely watched jurisdictions globally regarding regulated psychedelic-assisted psychotherapy frameworks.

The TGA’s ongoing adjustments to Authorised Prescriber guidelines continue to attract industry attention as healthcare providers and treatment developers assess how operational requirements may evolve over time.

For companies such as Emyria, workforce accessibility and therapist availability represent important operational considerations because psychedelic-assisted psychotherapy models typically require structured treatment teams and supervised clinical settings.

Broader therapist eligibility criteria may therefore assist companies seeking to scale clinic operations while maintaining compliance with regulatory requirements.

At the same time, the sector remains subject to evolving clinical evidence, regulatory oversight and ongoing patient safety considerations.

The company also reiterated standard cautionary statements regarding the use of MDMA, psilocybin and related compounds, noting that there are currently no TGA-approved products containing these substances that have been formally evaluated for quality, safety and efficacy.

What This Means for Investors

Emyria’s latest update appears to have been received positively by investors because the revised TGA recommendations may support therapist recruitment flexibility and clinic scalability across the company’s Empax network.

The broader clinician eligibility profile could help improve operational efficiency and patient access over time, particularly as Emyria continues expanding its psychedelic-assisted psychotherapy capabilities.

Investors are also likely monitoring how quickly the revised framework progresses through final approval stages and whether the changes translate into measurable operational benefits from H2 CY2026 onward.

While the regulatory framework remains subject to further review and implementation requirements, the announcement represents a potentially favourable operational development for Emyria’s mental health treatment platform.